Page 150 - NobleCon21

Health Care
Date November 20, 2025 Health Care
52wk High $3.07
52wk Low $0.30 SeaStar Medical Holding Co ICU $0.31
3513 Brighton Boulevard
Denver, CO 80216

(USD - in millions) seastarmedical.com
Market Cap 11.2
Enterprise (2.5)
Basic Shares Out. 36.05 COMPANY OVERVIEW
Float 35.78
Institutional Holdings 3.03% Detailed Analysis:Channelchek.com
Short Interest 0.62
Avg. 90-Day Volume 1.97 SeaStar Medical Holding Corporation, a commercial-stage medical
device company, develops a proprietary platform therapy to reduce the
consequences of hyperinflammation on vital organs in the United
States. The company offers the selective cytopheretic device (SCD),
EPS Data which is a disease-modifying device that neutralizes over-active
immune cells and stops the cytokine storm that yields destructive
2022 2023 2024 hyperinflammation; and QUELIMMUNE, an SCD therapy for pediatric
CQ1 N/A (10.00) (4.75) patients with acute kidney injury (AKI) due to sepsis. It also develops
CQ2 N/A (6.25) (1.03) NEUTRALIZE-AKI, an SCD therapy that is in clinical trials for adult
patients with AKI; and other products in various therapeutic areas,
CQ3 N/A (9.25) (1.10) including cardiorenal syndrome, hepatorenal syndrome, and myocardial
CQ4 N/A (4.75) (0.90) stunning in end-stage renal disease.
CY (70.00) (30.25) (6.63) Source: Channelchek/QuoteMedia

Long-Term EPS Estimate N/A
Price/Book (mrq) 0.34
ROE (ttm) -290.37
Debt-to-Total Cap. (mrq) N/A
Fiscal Year End 31-Dec
3513 Brighton Denver CO 80216

Key Executives
CEO: Schlorff, Eric
CFO: Messinger, Michael
COO: Mullen, Tom
IR: N/A
Noble Capital Markets, Inc.
Source: Capital IQ, Noble Financial estimates, company filings
Noble Senior Analyst 561-994-1191 noblecapitalmarkets.com
Robert LeBoyer MEMBERS: FINRA, SIPC, MSRB
rleboyer@noblelsp.com Following the conference, complete video library of presentations will be
available at: channelchek.com | nobleconference.com
(212) 896-4625

Refer to the back of the book for disclosures